about
Periprocedural glycemic control in patients with diabetes mellitus undergoing coronary angiography with possible percutaneous coronary intervention.Diabetes and vascular disease in different arterial territories.A risk score for prediction of hyperglycemia at coronary angiography.Predictors of Access Site Crossover in Patients Who Underwent Transradial Coronary AngiographyDiagnostic Accuracy of Cardiac Magnetic Resonance Imaging in the Evaluation of Newly Diagnosed Heart Failure With Reduced Left Ventricular Ejection Fraction.Quantitative Perfusion Analysis of First-Pass Contrast Enhancement Kinetics: Application to MRI of Myocardial Perfusion in Coronary Artery Disease.Colchicine: old and newPrevalence of unrecognized diabetes, prediabetes and metabolic syndrome in patients undergoing elective percutaneous coronary interventionMean platelet volume and long-term mortality in patients undergoing percutaneous coronary interventionEffect of Colchicine on Platelet-Platelet and Platelet-Leukocyte Interactions: a Pilot Study in Healthy SubjectsPeriprocedural management of the patient with diabetes mellitus undergoing coronary angiography: current practice.Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout.Radiation exposure during coronary angiography via transradial or transfemoral approaches when performed by experienced operators.Comparison of platelet activity measurements by use of arterial and venous blood sampling.Mean platelet volume reproducibility and association with platelet activity and anti-platelet therapy.Change in enrollment patterns, patient selection, and clinical outcomes with the availability of drug-eluting stents in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial.Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: an expert consensus document from the Society for Cardiovascular Angiography and Interventions (SCAI).Effectiveness of fluorography versus cineangiography at reducing radiation exposure during diagnostic coronary angiography.Temporal trends in clinical characteristics of patients without known cardiovascular disease with a first episode of myocardial infarction.Hyperglycemia in nondiabetic patients presenting with acute myocardial infarction.Drug-eluting stents: the past, present, and future.Late breaking trials of 2015 in coronary artery disease: Commentary covering ACC, EuroPCR, SCAI, TCT, ESC, and AHA.Revascularization Strategies in Patients with Diabetes Mellitus and Acute Coronary Syndrome.Effect of Percutaneous Coronary Intervention on Survival in Patients with Stable Ischemic Heart Disease.Relationship between neutrophil-lymphocyte ratio and severity of lower extremity peripheral artery disease.Glycemic Control in Coronary Revascularization.The assessment of thrombotic markers utilizing ionic versus non-ionic contrast during coronary angiography and intervention trial.Effect of Left Versus Right Radial Artery Approach for Coronary Angiography on Radiation Parameters in Patients With Predictors of Transradial Access Failure.Provoking conditions, management and outcomes of type 2 myocardial infarction and myocardial necrosis.Late breaking trials of 2016 in coronary artery disease: Commentary covering SCAI, ACC, TCT, EuroPCR, ESC, and AHA.Update on colchicine, 2017.Treatment and outcomes of type 2 myocardial infarction and myocardial injury compared with type 1 myocardial infarction.Association between diet quality and measures of body adiposity using the Rate Your Plate survey in patients presenting for coronary angiography.Impaired arterial responsiveness in untreated gout patients compared with healthy non-gout controls: association with serum urate and C-reactive protein.Transradial Artery Access in Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction and Cardiogenic Shock.The Effect of a Vegan versus AHA DiEt in Coronary Artery Disease (EVADE CAD) trial: study design and rationale.Outcomes after transcatheter aortic valve replacement in patients with low versus high gradient severe aortic stenosis in the setting of preserved left ventricular ejection fractionEarly Readmissions After ST-Segment-Elevation Myocardial Infarction: Glass Ceiling or Room for Improvement?Anti-Inflammatory Effects of a Vegan Diet Versus the American Heart Association-Recommended Diet in Coronary Artery Disease TrialTiming and Causes of Unplanned Readmissions After Percutaneous Coronary Intervention: Insights From the Nationwide Readmission Database
P50
Q33600990-831E2CBB-CD38-4965-BAEF-B2E61F6A9ACFQ33646596-AA515305-94F5-4C11-B137-C32651D1E323Q35519580-8349711E-5006-4E9F-9E80-D2DD1589E053Q35843476-6EB10AA0-8884-462E-8DAE-DF360D40D986Q36054409-8B1B171C-B424-4C6B-9E34-314D04A6B5D1Q36119540-200489FF-92C4-423F-BA39-2D0A6205BA32Q36384995-909F69A8-CAF6-496B-94E6-65759C2F9E3CQ36412515-1E788859-A48F-4A8A-9C49-4A323C43D523Q36514155-0DD191F7-76CD-4DCD-8A8E-CD0D580FC901Q36578681-96ED492F-058B-4F8C-AA7A-6EF6747411E1Q36621669-6AC2C39C-50CE-472F-9045-9F014DDE96A9Q37070180-4C22FDEB-C1D4-430A-8CC8-CF59A50ECAA8Q37070194-406F0F2E-D8A3-474D-94CF-5DCCC7FE6E70Q37252227-808A1ABB-FA7B-4D7B-AC49-A83449E35F2DQ37257153-64D62133-FEB1-4AE0-BD41-A8B6544236C7Q37403027-3B052B0C-7260-403D-92EF-327CCFA7F07DQ37472971-D5E0574F-23C6-4BC5-9AA4-9357ACCD28C7Q37646817-9BA64808-C171-4641-B921-D951F8D5AD6AQ37660644-A8545CF9-8FA5-4881-8234-975FF1B6C179Q37938635-B740DB17-467A-4CC6-82D4-40695DB25000Q38344198-857FDBE8-9639-4A89-8CC7-7E0B49A3FF85Q38762240-AE582D74-A557-423D-8DA8-D0FC6729A5F3Q38875527-5D539204-FBAC-4E2D-8881-CBCC04D47656Q38954467-9E244CD0-35E0-4BFE-BF88-849F8A5B8D4FQ39013979-B29BD652-438C-4FD3-BB62-7BD16745B08EQ40048851-71B92B9A-FC48-494C-8268-002E58207A34Q40101721-BA851158-5ED7-4129-893C-6CD75DDC71DDQ40689201-B1983416-33F8-499B-B47A-047BFADC410EQ42328524-9079B85D-B660-478F-A1F9-28E491828F75Q46724260-EE6EA1A4-0162-4121-B392-A171696EEA80Q47177948-6283609F-3A63-46F6-B62C-CD8988A5D7A9Q47815800-7A13C6A3-10F7-4939-AA2A-60394E7AB092Q48246547-EDE99FE7-846F-44EB-BD10-5B9716849CC6Q49946886-1CC17FD5-D2B5-4994-AC7E-0AF623908641Q51748038-6FE885E7-2469-4F06-8C2A-E4C0A9A08110Q52716318-FC95FE66-CE2A-44FE-BE75-D63FCAE1FA42Q57741346-6BA1FDBB-8541-45D7-B99B-417F3FC35280Q58127029-63771636-1D3C-42DA-9B92-389B82A93157Q63560429-28DEE702-3FD3-45F4-8E06-48F69FB3B2FAQ64112232-14064A51-496C-4863-82E2-594C1A4F1977
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Binita Shah
@en
Binita Shah
@nl
type
label
Binita Shah
@en
Binita Shah
@nl
prefLabel
Binita Shah
@en
Binita Shah
@nl
P31
P496
0000-0001-8872-8001